Special BD LSR Fortessa

特别 BD LSR Fortessa

基本信息

  • 批准号:
    8640430
  • 负责人:
  • 金额:
    $ 35.05万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2014
  • 资助国家:
    美国
  • 起止时间:
    2014-05-01 至 2015-04-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): The University of Wisconsin Carbone Cancer Center (UWCCC) Flow Cytometry Laboratory (Flow Lab) is a heavily utilized shared service on the University of Wisconsin-Madison campus available to researchers who are members as well as non-members of the UWCCC. The impact of the Flow Lab on biomedical research infrastructure at UW-Madison is significant. This Shared Instrumentation Grant is a request for funds that cover 80% (remaining 20% supported by the institution) of the total cost of a BD LSR Fortessa" (Fortessa) instrument to further enhance the capability and the capacity of the Flow Lab. The addition of the Fortessa will alleviate the 2-3 week wait times currently experienced by our users allowing timely analysis of clinical research samples. It will provide high laser power for increased resolution of cellular subpopulations and excitation wavelengths (561nm and 355nm) necessary for detection of newly developed fluorescent markers, and will include a High-Throughput Sampler option for increased efficiency and screening capability. This instrument will provide redundancy when the existing 5-laser LSR is undergoing maintenance and/or repair. The experienced staff, well-established daily Quality Control Procedures, Online Scheduling System and Educational Programs allow for seamless integration of the Fortessa into the Flow Lab. The Fortessa cytometer will impact the development of novel treatment strategies for various human pathologies and increase our understanding of human biology. Funded projects by major and minor users benefiting by addition of the Fortessa include (i) clinical trials for development of a prostate cancer vaccine (Doug McNeel), (ii) immunotherapeutic agents for melanoma (Paul Sondel), (iii) mouse models for CMML (Jing Zhang), (iv) rat models for genetic modulation of mammary cancer (Michael Gould), (v) modulating immune responses in ovarian cancer (Manish Patankar), (vi) Graft versus Host disease in allogeneic bone marrow transplant patients with hematologic malignancies, (vii) effect of biobehavioral factors on immune function (Erin Costanzo), (viii) fibrogenesis in kidney disease (Arjung Djamali), (ix) hematopoietic stem cell maturation into cardiomyocytes (Sean Palecek), (x) ventilatory control due to effects of inflammation on neuronal cells (Jyoti Watters), (xi) effect of genetic mutations in a zinc transporter on sphodylocheiro dysplastic form of Ehlers- Danlos Syndrome (David Eide), (xii) immune maturation and regulation in farm and non-farm raised children to better understand wheezing illnesses (David Gern), (xiii) transcription factors in tumor suppression and DNA damage (Randall Tibbets), and (xiv) development of anti-fungal vaccines (Marcel W¿thrich and Bruce Klein). Excellent institutional support in the form of 20% cost sharing of the total price of the Fortessa, salary support for trained technical staff, and the service agreement to maintain a fully functional and well-equipped cytometer will allow us to fulfill the research needs of major and minor users for the next 10 years.
描述(由申请人提供):威斯康星大学碳骨癌中心(UWCCC)流式细胞术实验室(Flow Lab)是威斯康星大学麦迪逊分校校园内使用率很高的共享服务,可供UWCCC成员和非成员的研究人员使用。Flow Lab对威斯康星大学麦迪逊分校的生物医学研究基础设施产生了重大影响。这项共享仪器赠款是一项资金申请,用于支付BD LSR Fortessa“(Fortessa)仪器总成本的80%(剩余20%由机构支持),以进一步增强Flow Lab的能力和容量。Fortessa的加入将缓解我们的用户目前所经历的2-3周的等待时间,从而能够及时分析临床研究样本。它将提供高激光功率,以提高细胞亚群的分辨率和检测新开发的荧光标记所需的激发波长(561 nm和355 nm),并将包括一个高通量采样器选项,以提高效率和筛选能力。当现有的5激光器LSR正在进行维护和/或维修时,该仪器将提供冗余。经验丰富的员工、完善的日常质量控制程序、在线调度系统和教育计划使Fortessa能够无缝地整合到Flow Lab中。Fortessa细胞仪将对各种人类疾病的新治疗策略的开发产生影响,并增加我们对人类生物学的理解。受益于Fortessa的主要和次要用户资助的项目包括:(I)前列腺癌疫苗的临床试验(Doug McNeel),(Ii)黑色素瘤免疫治疗剂(Paul Sondel),(Iii)CMML小鼠模型(张静),(Iv)乳腺癌遗传调节的大鼠模型,(V)卵巢癌免疫反应调节(Manish Patankar),(Vi)恶性血液病异基因骨髓移植患者的移植物抗宿主病,(Vii)生物行为因素对免疫功能的影响(Erin Costanzo),(Viii)肾脏疾病中的纤维化形成(Arjung Djamali),(Ix)造血干细胞成熟为心肌细胞(Sean Palecek),(X)因炎症对神经细胞的影响而进行的通气性控制(Jyoti Watters),(Xi)锌转运体基因突变对Shodylocheiro异型Ehters-Danlos综合征的影响(David Eide),(Xii)农场和非农场抚养的儿童的免疫成熟和调节,以更好地了解喘息性疾病(David Gern),(Xiii)肿瘤抑制和DNA损伤中的转录因子(Randall Tibbets),和(十四)开发抗真菌疫苗(Marcel Wéthrich和Bruce Klein)。优秀的制度支持,以20%的总价格分摊成本的形式 Fortessa,为训练有素的技术人员提供的工资支持,以及维护功能齐全和设备齐全的细胞仪的服务协议,将使我们能够满足主要和次要用户在未来10年的研究需求。

项目成果

期刊论文数量(3)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Short-term Immunopathological Changes Associated with Pulse Steroids/IVIG/Rituximab Therapy in Late Kidney Allograft Antibody Mediated Rejection.
  • DOI:
    10.34067/kid.0001082019
  • 发表时间:
    2020-05
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Degner KR;Wilson NA;Reese SR;Parajuli S;Aziz F;Garg N;Mohamed M;Singh T;Mandelbrot DA;Panzer SE;Redfield RR;Van Hyfte K;Zhong W;Hidalgo LG;Djamali A
  • 通讯作者:
    Djamali A
Autologous Mesenchymal Stromal Cells Prevent Transfusion-elicited Sensitization and Upregulate Transitional and Regulatory B Cells.
  • DOI:
    10.1097/txd.0000000000000827
  • 发表时间:
    2018-09
  • 期刊:
  • 影响因子:
    2.3
  • 作者:
    Zhang Z;Wilson NA;Chinnadurai R;Panzer SE;Redfield RR 3rd;Reese SR;Galipeau J;Djamali A
  • 通讯作者:
    Djamali A
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Manish S Patankar其他文献

Manish S Patankar的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Manish S Patankar', 18)}}的其他基金

Using a chemical biology approach to develop novel inhibitors of mitochondrial oxidative phosphorylation for the treatment of ovarian cancer
使用化学生物学方法开发用于治疗卵巢癌的新型线粒体氧化磷酸化抑制剂
  • 批准号:
    10260915
  • 财政年份:
    2022
  • 资助金额:
    $ 35.05万
  • 项目类别:
Using a chemical biology approach to develop novel inhibitors of mitochondrial oxidative phosphorylation for the treatment of ovarian cancer
使用化学生物学方法开发用于治疗卵巢癌的新型线粒体氧化磷酸化抑制剂
  • 批准号:
    10513296
  • 财政年份:
    2022
  • 资助金额:
    $ 35.05万
  • 项目类别:
Developing non-human primate models for ovarian cancer
开发卵巢癌的非人类灵长类动物模型
  • 批准号:
    10044729
  • 财政年份:
    2020
  • 资助金额:
    $ 35.05万
  • 项目类别:
Ovarian cancer diagnosis by monitoring immune cell bound MUC16 (CA125)
通过监测免疫细胞结合 MUC16 (CA125) 诊断卵巢癌
  • 批准号:
    8123435
  • 财政年份:
    2010
  • 资助金额:
    $ 35.05万
  • 项目类别:
Flow Cytometry Laboratory
流式细胞术实验室
  • 批准号:
    10626518
  • 财政年份:
    1997
  • 资助金额:
    $ 35.05万
  • 项目类别:
Flow Cytometry Laboratory Shared Resource
流式细胞术实验室共享资源
  • 批准号:
    10456689
  • 财政年份:
    1997
  • 资助金额:
    $ 35.05万
  • 项目类别:
Flow Cytometry Laboratory Shared Resource
流式细胞术实验室共享资源
  • 批准号:
    9923018
  • 财政年份:
  • 资助金额:
    $ 35.05万
  • 项目类别:
Flow Cytometry Laboratory Shared Resource
流式细胞术实验室共享资源
  • 批准号:
    9756883
  • 财政年份:
  • 资助金额:
    $ 35.05万
  • 项目类别:

相似海外基金

HLA-homozygous iPSC-cardiomyocytE Aggregate manufacturing technoLogies for allogenic cell therapy to the heart (HEAL)
HLA-纯合 iPSC-心肌细胞 用于心脏同种异体细胞治疗 (HEAL) 的聚集体制造技术
  • 批准号:
    10039902
  • 财政年份:
    2022
  • 资助金额:
    $ 35.05万
  • 项目类别:
    EU-Funded
Evaluation of the efficacy of LAT1 inhibitor to tumor stroma and immunity in an allogenic mouse model of colon cancer having abundant stroma.
在具有丰富基质的同种异体结肠癌小鼠模型中评估 LAT1 抑制剂对肿瘤基质和免疫的功效。
  • 批准号:
    21K15925
  • 财政年份:
    2021
  • 资助金额:
    $ 35.05万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Mechanism of kidney injury associated with graft-versus-host disease after allogenic stem cell transplantation
同种异体干细胞移植后移植物抗宿主病相关肾损伤的机制
  • 批准号:
    21K08410
  • 财政年份:
    2021
  • 资助金额:
    $ 35.05万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Clarification of the origin and maintenance mechanisms of junctional epithelium and identification of its stem cells using allogenic tooth germ transplantation
阐明交界上皮的起源和维持机制并利用同种异体牙胚移植鉴定其干细胞
  • 批准号:
    20K21672
  • 财政年份:
    2020
  • 资助金额:
    $ 35.05万
  • 项目类别:
    Grant-in-Aid for Challenging Research (Exploratory)
The study about the allogenic MSCs transplantation to the cardiac disease models.
同种异体间充质干细胞移植至心脏病模型的研究。
  • 批准号:
    18K16395
  • 财政年份:
    2018
  • 资助金额:
    $ 35.05万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Artificial nerves containing allogenic basal lamellae scaffold and bone marrow derived stem cells
含有同种异体基底板层支架和骨髓干细胞的人工神经
  • 批准号:
    17K10951
  • 财政年份:
    2017
  • 资助金额:
    $ 35.05万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Role of HSP90-alpha in preserving immunoprivilege of allogenic mesenchymal stem cells in the ischemic heart
HSP90-α 在保护缺血心脏同种异体间充质干细胞免疫特权中的作用
  • 批准号:
    370541
  • 财政年份:
    2017
  • 资助金额:
    $ 35.05万
  • 项目类别:
    Operating Grants
Attempt to Prefabricate Vascularized Allogenic Bone in Recipient -Use of Cultured Bone Marrow Cells-
尝试在受者体内预制血管化的同种异体骨 - 使用培养的骨髓细胞 -
  • 批准号:
    16K10863
  • 财政年份:
    2016
  • 资助金额:
    $ 35.05万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Allogenic micobiota-reconstitution (AMR) for the treatment of patients with diarhea-predominant irritable bowel syndrome (IBS-D) - the AMIRA trial
同种异体微生物群重建 (AMR) 用于治疗腹泻型肠易激综合征 (IBS-D) 患者 - AMIRA 试验
  • 批准号:
    276706135
  • 财政年份:
    2015
  • 资助金额:
    $ 35.05万
  • 项目类别:
    Clinical Trials
Induction of thyme epithelial cells from iPS cells and application to allogenic transplantation
iPS细胞诱导百里香上皮细胞及其在同种异体移植中的应用
  • 批准号:
    15H04915
  • 财政年份:
    2015
  • 资助金额:
    $ 35.05万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了